Keyphrases
Levosimendan
100%
Lymphoma
76%
Tumor
63%
Malignancy
46%
Tumor Progression
38%
Lewis Lung Carcinoma
37%
Tumor Cells
35%
Adriamycin
33%
B16 Melanoma
31%
Macrophages
31%
Aged Mice
28%
Polysaccharide
26%
Metastasis
22%
Spleen
22%
Cyclophosphamide
21%
Metastatic Cells
19%
Hyperthermia
19%
Inhibitory Effect
17%
Apoptosis
17%
Biological Behavior
16%
Tumor Growth
15%
Cell Membrane
15%
Primary Tumor Cells
14%
C57 Mice
14%
Metastatic Potential
14%
Cytotoxic Agents
13%
Cell-derived
13%
Drug Resistance
12%
Lewis Lung Carcinoma Cells
12%
Apoptotic Cells
12%
Metastatic Tumor
11%
Splenectomy
11%
Immune Response
10%
Malignancy Grade
10%
Combined Treatment
10%
Chemotherapy
10%
Primary Tumor
10%
Inoculation
10%
Tumor Microenvironment
10%
Nocardia
10%
Human Ovarian Cancer Cell
10%
Lymph Node
10%
Cell Proliferation
9%
Apoptotic Cell Death
9%
Cancer Treatment
8%
Lymphoma Cells
8%
Experimental Tumors
8%
Antitumoral Effect
8%
Melanoma
8%
Immunomodulator
7%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
89%
Mouse
74%
Levan
72%
Tumor Growth
56%
Lewis Carcinoma
43%
Doxorubicin
27%
Metastasis
26%
Malignant Neoplasm
25%
Primary Tumor
22%
Melanoma B16
21%
Hyperthermia
20%
Polysaccharide
14%
Cyclophosphamide
14%
Cytotoxic Agent
13%
Metastasis Potential
13%
Ovary Cancer
10%
Nocardia
10%
Chemotherapy
9%
Carcinogenicity
9%
Drug Resistance
8%
Experimental Neoplasm
7%
C57BL Mouse
7%
Immunotherapy
7%
Immunomodulating Agent
5%
Melanoma
5%
Medicine and Dentistry
Cancer
35%
Neoplasm
33%
Metastatic Carcinoma
29%
Tumor Progression
25%
Doxorubicin
23%
Primary Tumor
19%
Tumor Cell
18%
Melanoma B16
14%
Hyperthermia
13%
Metastasis Potential
13%
Levan
11%
Drug Resistance
8%
Cell Function
7%
Nodular Melanoma
7%
Immune Response
6%
Ovarian Cancer Cell Line
6%
Tumor Microenvironment
6%
Malignant Neoplasm
6%
Lymphoma Cell
6%
Cytotoxic Agent
6%
Splenectomy
5%
Multidrug Resistance
5%
Ovarian Cancer
5%
Cell Membrane
5%
Immunotherapy
5%